Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

4.455 -1.315 (-22.79%)
Streaming Delayed Price Updated: 2:24 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
News headline image
Why Is Nanocap Immuneering Stock Trading Higher On Friday? ↗
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate... 
Via Benzinga
News headline image
Why is Immuneering (IMRX) Stock Up 24% Today? ↗
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus. 
Via InvestorPlace
News headline image
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Nasdaq Surges 1%; Meta Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 ↗
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
News headline image
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
News headline image
3 Stocks Insiders Are Buying That Analysts Love
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
Via MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
Via AB Newswire
News headline image
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data ↗
Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues despite promising mechanism of action. Optimism remains for earlier-stage... 
Via Benzinga
News headline image
Dow Falls Over 200 Points; Adobe Shares Plunge ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
Crude Oil Edges Lower; US Consumer Sentiment Falls In March ↗
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
News headline image
What's Going On With Cancer-Focused Immuneering Stock On Thursday? ↗
Unlock the latest Phase 1 trial results for IMM-1-104 by Immuneering. Discover how 320mg and 240mg doses inhibit tumor progression and evaluate safety profiles. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.